Meeder Asset Management’s Harvard Bioscience HBIO Stock Holding History

Meeder Asset Management’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-9	Closed	–	–	2253
2020 Q2	$0	Hold	9	–	–	﹤0.01%	2216
2020 Q1	$0	Sell	9 -147	-94%	-$3.98K	﹤0.01%	2398
2019 Q4	$4K	Hold	156	–	–	﹤0.01%	1843
2019 Q3	$4K	Buy	156 +40	+34%	+$994	﹤0.01%	1822
2019 Q2	$2K	Buy	116 +11	+10%	+$322	﹤0.01%	1858
2019 Q1	$5K	Sell	105 -560	-84%	-$20.3K	﹤0.01%	1388
2018 Q4	$20K	Buy	665 +168	+34%	+$6.62K	﹤0.01%	1066
2018 Q3	$27K	Buy	+497	New	+$27.9K	﹤0.01%	950

Other funds holding HBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Meeder Asset Management's HBIO Position: Q3 2020 in Review

Meeder Asset Management sold out of Harvard Bioscience (HBIO) in Q3 2020, closing a stake of 9 shares.

Meeder Asset Management first reported a position in HBIO in Q3 2018 and held it in 8 quarters. The position peaked at $27K in Q3 2018. 85 funds tracked by Wall St. Rank hold HBIO as of Q3 2020.

Meeder Asset Management reported no remaining Harvard Bioscience position as of Q3 2020 after selling out during the quarter.
Meeder Asset Management sold 9 Harvard Bioscience shares in Q3 2020.
Meeder Asset Management first reported a position in Harvard Bioscience in Q3 2018 and held it in 8 quarters.
Meeder Asset Management's Harvard Bioscience position peaked at $27K in Q3 2018.
85 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2020.

Based on Meeder Asset Management's 13F filing for Q3 2020, filed 2 Nov 2020.